Botanix Pharmaceuticals Ltd BXPHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.76B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Botanix Pharmaceuticals Ltd is a pharmaceutical company. It launched Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used topically to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older. Its mechanism of action targets the M3 receptor in the sweat gland, blocking acetylcholine to reduce sweat at its source. Its segments include Australia and United States which generates all of the revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
- Website
- https://www.botanixpharma.com
Valuation
|
Metric
|
BXPHF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.49 |
Price/Sales | 0.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BXPHF
|
|---|---|
Quick Ratio | 1.40 |
Current Ratio | 2.59 |
Interest Coverage | −23.98 |
Quick Ratio
BXPHF
Profitability
|
Metric
|
BXPHF
|
|---|---|
Return on Assets (Normalized) | −54.80% |
Return on Equity (Normalized) | −91.96% |
Return on Invested Capital (Normalized) | −61.96% |
Return on Assets
BXPHF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t>JPY?l | LOCK|#?db | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>!<$>g | LOCK|<Hj?@ | $83B | |||
| Moderna Inc
MRNA
| LOCK|<!jb>d | LOCK|#L | $80B | |||
| argenx SE ADR
ARGX
| LOCK|HdM$!ZP | LOCK|VYx | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#r&C>S | LOCK|j^w | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?Z$TzwG | LOCK|l?G? | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|W%Lxl<! | LOCK|sWH@M | $28B | |||
| Incyte Corp
INCY
| LOCK|FW$DSV | LOCK|R# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<wR&M% | LOCK|!$k | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|sxGYdJC | LOCK|>@ | $14B |
United States